Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533823 | 0.83 | MAOA (0.40) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL273784 | 0.78 | PCSK9 (0.39) | — | |
| SCHEMBL27550594 | 0.77 | MAOA (0.43) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL21748441 | 0.77 | MAOA (0.43) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL6963563 | 0.77 | NAAA (0.41) | — | |
| SCHEMBL3930440 | 0.76 | MAOA (0.41) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL6960170 | 0.75 | NAAA (0.43) | — | |
| SCHEMBL10611414 | 0.74 | MAOA (0.40) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL3865502 | 0.74 | MGAM (0.40) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL28483509 | 0.74 | BCAT2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153774-A1 | INORGANIC POROUS CARRIER AND METHOD FOR PRODUCING NUCLEIC ACIDS USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153774-A1 | INORGANIC POROUS CARRIER AND METHOD FOR PRODUCING NUCLEIC ACIDS USING SAME | SLCO2A1, SLCO2B1, SLCO4C1 | MAOA 3745/4885HTR2A 3234/4885HRH1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.